Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. immorist

ImMoRiSt

Immune Monitoring for RIsk STratification in Solid Organ Transplant Recipients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ImMoRiSt project word cloud

Explore the words cloud of the ImMoRiSt project. It provides you a very rough idea of what is the project "ImMoRiSt" about.

mediated    yield    firm    qualitative    immunomonitoring    parallel    cells    biosciences    place    physicians    release    austria    ivd    germany    triggered    cocktail    lung    biomarker    function    explore    highest    strategy    blood    stimulants    clinically    logical    strength    final    transplantation    recipients    stimulate    obtain    sot    performed    ifn    monitoring    validation    liver    heart    marking    approval    freedom    patients    solid    selectively    patient    outcome    complications    uses    competitor    caused    relatively    immune    grow    transplant    feasibility    cell    plan    24    leader    provides    validate    frequency    gamma    functional    operate    improves    immunosuppressive    setting    ce    proprietary    infections    scan    transplanted    global    diagnostic    pursued    dosage    clinical    detection    links    lophius    entry    interferon    tests    right    centers    organ    drugs    switzerland    regulatory    suited    quantitative    business    every    kidney    rejection    obtaining    market   

Project "ImMoRiSt" data sheet

The following table provides information about the project.

Coordinator		 LOPHIUS BIOSCIENCES GMBH 

Organization address
address: AM BIOPARK 13
city: REGENSBURG
postcode: 93053
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOPHIUS BIOSCIENCES GMBH DE (REGENSBURG) coordinator 50˙000.00

Map

 Project objective

Every year ~ 40.000 patients throughout the EU are transplanted a new kidney, lung, liver, heart or another organ. The frequency of clinical complications is relatively high because at present there are no diagnostic tests that help physicians to determine the right dosage of immunosuppressive drugs necessary to avoid both organ rejection and clinical complications caused by infections.

Lophius Biosciences GmbH has developed I-Scan, a functional immune monitoring test that within 24 h provides important information on the strength of the immune system in solid organ transplant recipients. I-Scan uses a proprietary cocktail of stimulants that selectively stimulate the clinically relevant immune cells in a patient’s blood sample. The detection of the triggered interferon γ (IFN-γ) release provides a qualitative and quantitative measurement of cell-mediated immune function.

The feasibility study performed during Phase 1 will explore issues related to both, the clinical biomarker validation study and the best market entry strategy. Several objectives are pursued in parallel and encompass: • Setting up the business plan which includes a competitor as well as a freedom-to-operate analysis and a market entry strategy. • Selection of clinical study partners and defining the design of the clinical study, best suited to yield highest clinical evidence • Obtaining regulatory approval for the planned clinical study and setting a strategy to obtain regulatory approval / CE-Marking for final I-Scan products.

Lophius will apply for Phase 2 funding of a clinical study to validate that I-Scan improves the outcome of SOT patients. This study is likely to take place in Germany, Switzerland and Austria where Lophius has already established firm links to transplantation centers. The study is the logical next step to further grow Lophius to become a global leader in the IVD market for immunomonitoring

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMORIST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMORIST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More